APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Overactive Bladder (OAB) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Overactive Bladder (OAB) Therapeutics Market Analysis and Forecast 2026-2032

Report ID 174021300220 December 2025198 pages

Choose your research edition.

Industry ResearchOveractive Bladder (OAB) Therapeutics Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Overactive Bladder (OAB) Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Overactive Bladder (OAB) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Overactive Bladder (OAB) Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Overactive Bladder (OAB) Therapeutics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Overactive Bladder (OAB) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Overactive Bladder (OAB) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Overactive Bladder (OAB) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Overactive Bladder (OAB) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Overactive Bladder (OAB) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Overactive Bladder (OAB) Therapeutics include Allergan, Astellas Pharma, Hisamitsu Pharmaceutical, Ion Channel Innovations, Kwang Dong Pharmaceutical, ONO Pharmaceutical, Tengion, GlaxoSmithKline and Ferring, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Overactive Bladder (OAB) Therapeutics, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Overactive Bladder (OAB) Therapeutics, also provides the sales of main regions and countries. Of the upcoming market potential for Overactive Bladder (OAB) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Overactive Bladder (OAB) Therapeutics sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Overactive Bladder (OAB) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Overactive Bladder (OAB) Therapeutics sales, projected growth trends, production technology, application and end-user industry.

Overactive Bladder (OAB) Therapeutics Segment by Company

Allergan

Astellas Pharma

Hisamitsu Pharmaceutical

Ion Channel Innovations

Kwang Dong Pharmaceutical

ONO Pharmaceutical

Tengion

GlaxoSmithKline

Ferring

Pfizer

Lanzhou Institute of Biological Products

Merck

Sanofi

Teva Pharmaceutical Industries

Overactive Bladder (OAB) Therapeutics Segment by Type

Anticholinergic Agents

Beta-3 Adrenoreceptor Agonists

Overactive Bladder (OAB) Therapeutics Segment by Application

Hosptial

Clinci

Other

Overactive Bladder (OAB) Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Overactive Bladder (OAB) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Overactive Bladder (OAB) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Overactive Bladder (OAB) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Overactive Bladder (OAB) Therapeutics in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Overactive Bladder (OAB) Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Overactive Bladder (OAB) Therapeutics sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Anticholinergic Agents Major Manufacturers Table 3. Beta-3 Adrenoreceptor Agonists Major Manufacturers Table 4. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hosptial Major Manufacturers Table 6. Clinci Major Manufacturers Table 7. Other Major Manufacturers Table 8. Overactive Bladder (OAB) Therapeutics Industry Trends Table 9. Overactive Bladder (OAB) Therapeutics Industry Drivers Table 10. Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges Table 11. Overactive Bladder (OAB) Therapeutics Industry Restraints Table 12. Global Overactive Bladder (OAB) Therapeutics Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2021-2026) Table 16. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2027-2032) Table 17. Global Overactive Bladder (OAB) Therapeutics Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2026) & (K Units) Table 19. Global Overactive Bladder (OAB) Therapeutics Sales by Region (2027-2032) & (K Units) Table 20. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2021-2026) Table 21. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2027-2032) Table 22. Global Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2021-2026) Table 26. Global Overactive Bladder (OAB) Therapeutics Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Overactive Bladder (OAB) Therapeutics Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Overactive Bladder (OAB) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Overactive Bladder (OAB) Therapeutics Manufacturers, Product Type & Application Table 30. Global Overactive Bladder (OAB) Therapeutics Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Overactive Bladder (OAB) Therapeutics by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Overactive Bladder (OAB) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2021-2026) Table 37. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2027-2032) Table 38. Global Overactive Bladder (OAB) Therapeutics Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 40. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (K Units) Table 41. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2021-2026) Table 42. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2027-2032) Table 43. Global Overactive Bladder (OAB) Therapeutics Price by Type (2021-2026) & (US$/Unit) Table 44. Global Overactive Bladder (OAB) Therapeutics Price by Type (2027-2032) & (US$/Unit) Table 45. Global Overactive Bladder (OAB) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2021-2026) Table 49. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2027-2032) Table 50. Global Overactive Bladder (OAB) Therapeutics Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 52. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (K Units) Table 53. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2021-2026) Table 54. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2027-2032) Table 55. Global Overactive Bladder (OAB) Therapeutics Price by Application (2021-2026) & (US$/Unit) Table 56. Global Overactive Bladder (OAB) Therapeutics Price by Application (2027-2032) & (US$/Unit) Table 57. Allergan Company Information Table 58. Allergan Business Overview Table 59. Allergan Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio Table 61. Allergan Recent Development Table 62. Astellas Pharma Company Information Table 63. Astellas Pharma Business Overview Table 64. Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio Table 66. Astellas Pharma Recent Development Table 67. Hisamitsu Pharmaceutical Company Information Table 68. Hisamitsu Pharmaceutical Business Overview Table 69. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 71. Hisamitsu Pharmaceutical Recent Development Table 72. Ion Channel Innovations Company Information Table 73. Ion Channel Innovations Business Overview Table 74. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio Table 76. Ion Channel Innovations Recent Development Table 77. Kwang Dong Pharmaceutical Company Information Table 78. Kwang Dong Pharmaceutical Business Overview Table 79. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 81. Kwang Dong Pharmaceutical Recent Development Table 82. ONO Pharmaceutical Company Information Table 83. ONO Pharmaceutical Business Overview Table 84. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio Table 86. ONO Pharmaceutical Recent Development Table 87. Tengion Company Information Table 88. Tengion Business Overview Table 89. Tengion Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio Table 91. Tengion Recent Development Table 92. GlaxoSmithKline Company Information Table 93. GlaxoSmithKline Business Overview Table 94. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio Table 96. GlaxoSmithKline Recent Development Table 97. Ferring Company Information Table 98. Ferring Business Overview Table 99. Ferring Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio Table 101. Ferring Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio Table 106. Pfizer Recent Development Table 107. Lanzhou Institute of Biological Products Company Information Table 108. Lanzhou Institute of Biological Products Business Overview Table 109. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio Table 111. Lanzhou Institute of Biological Products Recent Development Table 112. Merck Company Information Table 113. Merck Business Overview Table 114. Merck Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Merck Overactive Bladder (OAB) Therapeutics Product Portfolio Table 116. Merck Recent Development Table 117. Sanofi Company Information Table 118. Sanofi Business Overview Table 119. Sanofi Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio Table 121. Sanofi Recent Development Table 122. Teva Pharmaceutical Industries Company Information Table 123. Teva Pharmaceutical Industries Business Overview Table 124. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio Table 126. Teva Pharmaceutical Industries Recent Development Table 127. North America Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Overactive Bladder (OAB) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 130. North America Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (K Units) Table 131. North America Overactive Bladder (OAB) Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 132. North America Overactive Bladder (OAB) Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 133. North America Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 134. North America Overactive Bladder (OAB) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 135. North America Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 136. North America Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (K Units) Table 137. North America Overactive Bladder (OAB) Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 138. North America Overactive Bladder (OAB) Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 139. North America Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. North America Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 141. North America Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 142. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 143. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 144. North America Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 145. North America Overactive Bladder (OAB) Therapeutics Sales Price by Country (2021-2026) & (US$/Unit) Table 146. North America Overactive Bladder (OAB) Therapeutics Sales Price by Country (2027-2032) & (US$/Unit) Table 147. United States Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 148. Canada Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 149. Europe Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 150. Europe Overactive Bladder (OAB) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 151. Europe Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 152. Europe Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (K Units) Table 153. Europe Overactive Bladder (OAB) Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 154. Europe Overactive Bladder (OAB) Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 155. Europe Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 156. Europe Overactive Bladder (OAB) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 157. Europe Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 158. Europe Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (K Units) Table 159. Europe Overactive Bladder (OAB) Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 160. Europe Overactive Bladder (OAB) Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 161. Europe Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Europe Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 163. Europe Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 164. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 165. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 166. Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 167. Europe Overactive Bladder (OAB) Therapeutics Sales Price by Country (2021-2026) & (US$/Unit) Table 168. Europe Overactive Bladder (OAB) Therapeutics Sales Price by Country (2027-2032) & (US$/Unit) Table 169. Germany Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 170. France Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 171. U.K. Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 172. Italy Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 173. Netherlands Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 174. China Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 175. China Overactive Bladder (OAB) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 176. China Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 177. China Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (K Units) Table 178. China Overactive Bladder (OAB) Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 179. China Overactive Bladder (OAB) Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 180. China Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 181. China Overactive Bladder (OAB) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 182. China Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 183. China Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (K Units) Table 184. China Overactive Bladder (OAB) Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 185. China Overactive Bladder (OAB) Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 186. Asia Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 187. Asia Overactive Bladder (OAB) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 188. Asia Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 189. Asia Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (K Units) Table 190. Asia Overactive Bladder (OAB) Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 191. Asia Overactive Bladder (OAB) Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 192. Asia Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 193. Asia Overactive Bladder (OAB) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 194. Asia Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 195. Asia Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (K Units) Table 196. Asia Overactive Bladder (OAB) Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 197. Asia Overactive Bladder (OAB) Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 198. Asia Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 199. Asia Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 200. Asia Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 201. Asia Overactive Bladder (OAB) Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 202. Asia Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 203. Asia Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 204. Asia Overactive Bladder (OAB) Therapeutics Sales Price by Country (2021-2026) & (US$/Unit) Table 205. Asia Overactive Bladder (OAB) Therapeutics Sales Price by Country (2027-2032) & (US$/Unit) Table 206. Japan Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 207. South Korea Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 208. India Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 209. Australia Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 210. China Taiwan Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 211. Southeast Asia Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 212. SAMEA Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 213. SAMEA Overactive Bladder (OAB) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 214. SAMEA Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2026) & (K Units) Table 215. SAMEA Overactive Bladder (OAB) Therapeutics Sales by Type (2027-2032) & (K Units) Table 216. SAMEA Overactive Bladder (OAB) Therapeutics Sales Price by Type (2021-2026) & (US$/Unit) Table 217. SAMEA Overactive Bladder (OAB) Therapeutics Sales Price by Type (2027-2032) & (US$/Unit) Table 218. SAMEA Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 219. SAMEA Overactive Bladder (OAB) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 220. SAMEA Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2026) & (K Units) Table 221. SAMEA Overactive Bladder (OAB) Therapeutics Sales by Application (2027-2032) & (K Units) Table 222. SAMEA Overactive Bladder (OAB) Therapeutics Sales Price by Application (2021-2026) & (US$/Unit) Table 223. SAMEA Overactive Bladder (OAB) Therapeutics Sales Price by Application (2027-2032) & (US$/Unit) Table 224. SAMEA Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 225. SAMEA Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 226. SAMEA Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 227. SAMEA Overactive Bladder (OAB) Therapeutics Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 228. SAMEA Overactive Bladder (OAB) Therapeutics Sales by Country (2021-2026) & (K Units) Table 229. SAMEA Overactive Bladder (OAB) Therapeutics Sales by Country (2027-2032) & (K Units) Table 230. SAMEA Overactive Bladder (OAB) Therapeutics Sales Price by Country (2021-2026) & (US$/Unit) Table 231. SAMEA Overactive Bladder (OAB) Therapeutics Sales Price by Country (2027-2032) & (US$/Unit) Table 232. Brazil Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 233. Argentina Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 234. Chile Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 235. Colombia Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 236. Peru Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 237. Saudi Arabia Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 238. Israel Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 239. UAE Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 240. Turkey Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 241. Iran Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 242. Egypt Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Table 243. Key Raw Materials Table 244. Raw Materials Key Suppliers Table 245. Overactive Bladder (OAB) Therapeutics Distributors List Table 246. Overactive Bladder (OAB) Therapeutics Customers List Table 247. Research Programs/Design for This Report Table 248. Authors List of This Report Table 249. Secondary Sources Table 250. Primary Sources List of Figures Figure 1. Overactive Bladder (OAB) Therapeutics Image Figure 2. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Overactive Bladder (OAB) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Anticholinergic Agents Image Figure 5. Beta-3 Adrenoreceptor Agonists Image Figure 6. Global Overactive Bladder (OAB) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Overactive Bladder (OAB) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hosptial Image Figure 9. Clinci Image Figure 10. Other Image Figure 11. Global Overactive Bladder (OAB) Therapeutics Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Overactive Bladder (OAB) Therapeutics Revenue (2021-2032) & (US$ Million) Figure 13. Global Overactive Bladder (OAB) Therapeutics Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2021-2032) Figure 16. Global Overactive Bladder (OAB) Therapeutics Sales (2021-2032) & (K Units) Figure 17. Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Overactive Bladder (OAB) Therapeutics Sales YoY (2021-2032) & (K Units) Figure 20. Europe Overactive Bladder (OAB) Therapeutics Sales YoY (2021-2032) & (K Units) Figure 21. China Overactive Bladder (OAB) Therapeutics Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Overactive Bladder (OAB) Therapeutics Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Overactive Bladder (OAB) Therapeutics Sales YoY (2021-2032) & (K Units) Figure 24. Global Overactive Bladder (OAB) Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Overactive Bladder (OAB) Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2021-2032) Figure 30. Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2021-2032) Figure 33. Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2021-2032) Figure 36. Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2021-2032) Figure 39. North America Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2021-2032) Figure 40. North America Overactive Bladder (OAB) Therapeutics Sales Share by Type (2021-2032) Figure 41. North America Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2021-2032) Figure 42. North America Overactive Bladder (OAB) Therapeutics Sales Share by Application (2021-2032) Figure 43. North America Overactive Bladder (OAB) Therapeutics Revenue Share by Country (2021-2032) Figure 44. North America Overactive Bladder (OAB) Therapeutics Sales Share by Country (2021-2032) Figure 45. Europe Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2021-2032) Figure 46. Europe Overactive Bladder (OAB) Therapeutics Sales Share by Type (2021-2032) Figure 47. Europe Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2021-2032) Figure 48. Europe Overactive Bladder (OAB) Therapeutics Sales Share by Application (2021-2032) Figure 49. Europe Overactive Bladder (OAB) Therapeutics Revenue Share by Country (2021-2032) Figure 50. Europe Overactive Bladder (OAB) Therapeutics Sales Share by Country (2021-2032) Figure 51. China Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2021-2032) Figure 52. China Overactive Bladder (OAB) Therapeutics Sales Share by Type (2021-2032) Figure 53. China Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2021-2032) Figure 54. China Overactive Bladder (OAB) Therapeutics Sales Share by Application (2021-2032) Figure 55. Asia Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2021-2032) Figure 56. Asia Overactive Bladder (OAB) Therapeutics Sales Share by Type (2021-2032) Figure 57. Asia Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2021-2032) Figure 58. Asia Overactive Bladder (OAB) Therapeutics Sales Share by Application (2021-2032) Figure 59. Asia Overactive Bladder (OAB) Therapeutics Revenue Share by Country (2021-2032) Figure 60. Asia Overactive Bladder (OAB) Therapeutics Sales Share by Country (2021-2032) Figure 61. SAMEA Overactive Bladder (OAB) Therapeutics Revenue Share by Type (2021-2032) Figure 62. SAMEA Overactive Bladder (OAB) Therapeutics Sales Share by Type (2021-2032) Figure 63. SAMEA Overactive Bladder (OAB) Therapeutics Revenue Share by Application (2021-2032) Figure 64. SAMEA Overactive Bladder (OAB) Therapeutics Sales Share by Application (2021-2032) Figure 65. SAMEA Overactive Bladder (OAB) Therapeutics Revenue Share by Country (2021-2032) Figure 66. SAMEA Overactive Bladder (OAB) Therapeutics Sales Share by Country (2021-2032) Figure 67. Overactive Bladder (OAB) Therapeutics Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Overactive Bladder (OAB) Therapeutics Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergic Agents
  • Beta-3 Adrenoreceptor Agonists
Applications
  • Hosptial
  • Clinci
  • Other
Companies covered
  • Allergan
  • Astellas Pharma
  • Hisamitsu Pharmaceutical
  • Ion Channel Innovations
  • Kwang Dong Pharmaceutical
  • ONO Pharmaceutical
  • Tengion
  • GlaxoSmithKline
  • Ferring
  • Pfizer
  • Lanzhou Institute of Biological Products
  • Merck
  • Sanofi
  • Teva Pharmaceutical Industries

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Overactive Bladder (OAB) Therapeutics Market by Type
  3. 1.2.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Anticholinergic Agents
  5. 1.2.3 Beta-3 Adrenoreceptor Agonists
  6. 1.3 Overactive Bladder (OAB) Therapeutics Market by Application
  7. 1.3.1 Global Overactive Bladder (OAB) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hosptial
  9. 1.3.3 Clinci
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Overactive Bladder (OAB) Therapeutics Market Dynamics
  1. 2.1 Overactive Bladder (OAB) Therapeutics Industry Trends
  2. 2.2 Overactive Bladder (OAB) Therapeutics Industry Drivers
  3. 2.3 Overactive Bladder (OAB) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Overactive Bladder (OAB) Therapeutics Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Overactive Bladder (OAB) Therapeutics Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Region
  3. 3.2.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2021-2026)
  5. 3.2.3 Global Overactive Bladder (OAB) Therapeutics Revenue by Region (2027-2032)
  6. 3.2.4 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Overactive Bladder (OAB) Therapeutics Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Overactive Bladder (OAB) Therapeutics Sales by Region
  9. 3.4.1 Global Overactive Bladder (OAB) Therapeutics Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Overactive Bladder (OAB) Therapeutics Sales by Region (2021-2026)
  11. 3.4.3 Global Overactive Bladder (OAB) Therapeutics Sales by Region (2027-2032)
  12. 3.4.4 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers
  2. 4.1.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Overactive Bladder (OAB) Therapeutics Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers
  6. 4.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Overactive Bladder (OAB) Therapeutics Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Overactive Bladder (OAB) Therapeutics Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Overactive Bladder (OAB) Therapeutics Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Overactive Bladder (OAB) Therapeutics Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Overactive Bladder (OAB) Therapeutics Manufacturers, Product Type & Application
  13. 4.7 Global Overactive Bladder (OAB) Therapeutics Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Overactive Bladder (OAB) Therapeutics Market CR5 and HHI
  16. 4.8.2 2025 Overactive Bladder (OAB) Therapeutics Tier 1, Tier 2, and Tier 3
5 Overactive Bladder (OAB) Therapeutics Market by Type
  1. 5.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Type
  2. 5.1.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Overactive Bladder (OAB) Therapeutics Sales by Type
  6. 5.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Type (2021-2032)
  9. 5.3 Global Overactive Bladder (OAB) Therapeutics Price by Type
6 Overactive Bladder (OAB) Therapeutics Market by Application
  1. 6.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Application
  2. 6.1.1 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Overactive Bladder (OAB) Therapeutics Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Overactive Bladder (OAB) Therapeutics Sales by Application
  6. 6.2.1 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Overactive Bladder (OAB) Therapeutics Sales Market Share by Application (2021-2032)
  9. 6.3 Global Overactive Bladder (OAB) Therapeutics Price by Application
7 Company Profiles
  1. 7.1 Allergan
  2. 7.1.1 Allergan Company Information
  3. 7.1.2 Allergan Business Overview
  4. 7.1.3 Allergan Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Overactive Bladder (OAB) Therapeutics Product Portfolio
  6. 7.1.5 Allergan Recent Developments
  7. 7.2 Astellas Pharma
  8. 7.2.1 Astellas Pharma Company Information
  9. 7.2.2 Astellas Pharma Business Overview
  10. 7.2.3 Astellas Pharma Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Astellas Pharma Overactive Bladder (OAB) Therapeutics Product Portfolio
  12. 7.2.5 Astellas Pharma Recent Developments
  13. 7.3 Hisamitsu Pharmaceutical
  14. 7.3.1 Hisamitsu Pharmaceutical Company Information
  15. 7.3.2 Hisamitsu Pharmaceutical Business Overview
  16. 7.3.3 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Hisamitsu Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  18. 7.3.5 Hisamitsu Pharmaceutical Recent Developments
  19. 7.4 Ion Channel Innovations
  20. 7.4.1 Ion Channel Innovations Company Information
  21. 7.4.2 Ion Channel Innovations Business Overview
  22. 7.4.3 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Ion Channel Innovations Overactive Bladder (OAB) Therapeutics Product Portfolio
  24. 7.4.5 Ion Channel Innovations Recent Developments
  25. 7.5 Kwang Dong Pharmaceutical
  26. 7.5.1 Kwang Dong Pharmaceutical Company Information
  27. 7.5.2 Kwang Dong Pharmaceutical Business Overview
  28. 7.5.3 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Kwang Dong Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  30. 7.5.5 Kwang Dong Pharmaceutical Recent Developments
  31. 7.6 ONO Pharmaceutical
  32. 7.6.1 ONO Pharmaceutical Company Information
  33. 7.6.2 ONO Pharmaceutical Business Overview
  34. 7.6.3 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 ONO Pharmaceutical Overactive Bladder (OAB) Therapeutics Product Portfolio
  36. 7.6.5 ONO Pharmaceutical Recent Developments
  37. 7.7 Tengion
  38. 7.7.1 Tengion Company Information
  39. 7.7.2 Tengion Business Overview
  40. 7.7.3 Tengion Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Tengion Overactive Bladder (OAB) Therapeutics Product Portfolio
  42. 7.7.5 Tengion Recent Developments
  43. 7.8 GlaxoSmithKline
  44. 7.8.1 GlaxoSmithKline Company Information
  45. 7.8.2 GlaxoSmithKline Business Overview
  46. 7.8.3 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 GlaxoSmithKline Overactive Bladder (OAB) Therapeutics Product Portfolio
  48. 7.8.5 GlaxoSmithKline Recent Developments
  49. 7.9 Ferring
  50. 7.9.1 Ferring Company Information
  51. 7.9.2 Ferring Business Overview
  52. 7.9.3 Ferring Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Ferring Overactive Bladder (OAB) Therapeutics Product Portfolio
  54. 7.9.5 Ferring Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Overactive Bladder (OAB) Therapeutics Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 Lanzhou Institute of Biological Products
  62. 7.11.1 Lanzhou Institute of Biological Products Company Information
  63. 7.11.2 Lanzhou Institute of Biological Products Business Overview
  64. 7.11.3 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Lanzhou Institute of Biological Products Overactive Bladder (OAB) Therapeutics Product Portfolio
  66. 7.11.5 Lanzhou Institute of Biological Products Recent Developments
  67. 7.12 Merck
  68. 7.12.1 Merck Company Information
  69. 7.12.2 Merck Business Overview
  70. 7.12.3 Merck Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Merck Overactive Bladder (OAB) Therapeutics Product Portfolio
  72. 7.12.5 Merck Recent Developments
  73. 7.13 Sanofi
  74. 7.13.1 Sanofi Company Information
  75. 7.13.2 Sanofi Business Overview
  76. 7.13.3 Sanofi Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Sanofi Overactive Bladder (OAB) Therapeutics Product Portfolio
  78. 7.13.5 Sanofi Recent Developments
  79. 7.14 Teva Pharmaceutical Industries
  80. 7.14.1 Teva Pharmaceutical Industries Company Information
  81. 7.14.2 Teva Pharmaceutical Industries Business Overview
  82. 7.14.3 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Teva Pharmaceutical Industries Overactive Bladder (OAB) Therapeutics Product Portfolio
  84. 7.14.5 Teva Pharmaceutical Industries Recent Developments
8 North America
  1. 8.1 North America Overactive Bladder (OAB) Therapeutics Market Size by Type
  2. 8.1.1 North America Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2032)
  3. 8.1.2 North America Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032)
  4. 8.1.3 North America Overactive Bladder (OAB) Therapeutics Price by Type (2021-2032)
  5. 8.2 North America Overactive Bladder (OAB) Therapeutics Market Size by Application
  6. 8.2.1 North America Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2032)
  7. 8.2.2 North America Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032)
  8. 8.2.3 North America Overactive Bladder (OAB) Therapeutics Price by Application (2021-2032)
  9. 8.3 North America Overactive Bladder (OAB) Therapeutics Market Size by Country
  10. 8.3.1 North America Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Overactive Bladder (OAB) Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Overactive Bladder (OAB) Therapeutics Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Overactive Bladder (OAB) Therapeutics Market Size by Type
  2. 9.1.1 Europe Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2032)
  3. 9.1.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032)
  4. 9.1.3 Europe Overactive Bladder (OAB) Therapeutics Price by Type (2021-2032)
  5. 9.2 Europe Overactive Bladder (OAB) Therapeutics Market Size by Application
  6. 9.2.1 Europe Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2032)
  7. 9.2.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032)
  8. 9.2.3 Europe Overactive Bladder (OAB) Therapeutics Price by Application (2021-2032)
  9. 9.3 Europe Overactive Bladder (OAB) Therapeutics Market Size by Country
  10. 9.3.1 Europe Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Overactive Bladder (OAB) Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Overactive Bladder (OAB) Therapeutics Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Overactive Bladder (OAB) Therapeutics Market Size by Type
  2. 10.1.1 China Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2032)
  3. 10.1.2 China Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032)
  4. 10.1.3 China Overactive Bladder (OAB) Therapeutics Price by Type (2021-2032)
  5. 10.2 China Overactive Bladder (OAB) Therapeutics Market Size by Application
  6. 10.2.1 China Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2032)
  7. 10.2.2 China Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032)
  8. 10.2.3 China Overactive Bladder (OAB) Therapeutics Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Overactive Bladder (OAB) Therapeutics Market Size by Type
  2. 11.1.1 Asia Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2032)
  3. 11.1.2 Asia Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032)
  4. 11.1.3 Asia Overactive Bladder (OAB) Therapeutics Price by Type (2021-2032)
  5. 11.2 Asia Overactive Bladder (OAB) Therapeutics Market Size by Application
  6. 11.2.1 Asia Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2032)
  7. 11.2.2 Asia Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032)
  8. 11.2.3 Asia Overactive Bladder (OAB) Therapeutics Price by Application (2021-2032)
  9. 11.3 Asia Overactive Bladder (OAB) Therapeutics Market Size by Country
  10. 11.3.1 Asia Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Overactive Bladder (OAB) Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Overactive Bladder (OAB) Therapeutics Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Overactive Bladder (OAB) Therapeutics Market Size by Type
  2. 12.1.1 SAMEA Overactive Bladder (OAB) Therapeutics Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Overactive Bladder (OAB) Therapeutics Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Overactive Bladder (OAB) Therapeutics Price by Type (2021-2032)
  5. 12.2 SAMEA Overactive Bladder (OAB) Therapeutics Market Size by Application
  6. 12.2.1 SAMEA Overactive Bladder (OAB) Therapeutics Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Overactive Bladder (OAB) Therapeutics Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Overactive Bladder (OAB) Therapeutics Price by Application (2021-2032)
  9. 12.3 SAMEA Overactive Bladder (OAB) Therapeutics Market Size by Country
  10. 12.3.1 SAMEA Overactive Bladder (OAB) Therapeutics Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Overactive Bladder (OAB) Therapeutics Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Overactive Bladder (OAB) Therapeutics Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Overactive Bladder (OAB) Therapeutics Value Chain Analysis
  2. 13.1.1 Overactive Bladder (OAB) Therapeutics Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Overactive Bladder (OAB) Therapeutics Production Mode & Process
  6. 13.2 Overactive Bladder (OAB) Therapeutics Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Overactive Bladder (OAB) Therapeutics Distributors
  9. 13.2.3 Overactive Bladder (OAB) Therapeutics Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst